{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:44:04Z","timestamp":1793659444684,"version":"4.5.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, associated with acute inflammation, and may increase subsequent cardiovascular disease (CVD) risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Determine whether AECOPD events are associated with increased risk of subsequent CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a secondary cohort analysis of the SUMMIT (Study to Understand Mortality and Morbidity) trial, a convenience sample of current\/former smokers with moderate COPD from 1,368 centers in 43 countries. All had CVD or increased CVD risk. AECOPD was defined as an increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids, and\/or hospitalization. CVD events were a composite outcome of cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. All CVD events were adjudicated. Cox proportional hazards models compared the hazard for a CVD event before AECOPD versus after AECOPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Among 16,485 participants in SUMMIT, 4,704 participants had at least one AECOPD and 688 had at least one CVD event. The hazard ratio (HR) for CVD events after AECOPD was increased, particularly in the first 30 days after AECOPD (HR, 3.8; 95% confidence interval, 2.7\u20135.5) and was elevated up to 1 year after AECOPD. The 30-day HR after hospitalized AECOPD was more than twofold greater (HR, 9.9; 95% confidence interval, 6.6\u201314.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with COPD with CVD or risk factors for CVD, exacerbations confer an increased risk of subsequent CVD events, especially in hospitalized patients and within the first 30 days after exacerbation. Patients and clinicians should have heightened vigilance for early CVD events after AECOPD.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 01313676).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201711-2239oc","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T11:05:14Z","timestamp":1518606314000},"page":"51-57","source":"Crossref","is-referenced-by-count":333,"title":["Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A\n                    <i>Post Hoc<\/i>\n                    Cohort Analysis from the SUMMIT Randomized Clinical Trial"],"prefix":"10.1093","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-2827","authenticated-orcid":false,"given":"Ken M.","family":"Kunisaki","sequence":"first","affiliation":[{"name":"Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota"},{"name":"University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Dransfield","sequence":"additional","affiliation":[{"name":"Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama"},{"name":"Birmingham Veterans Affairs Medical Center, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Stockley Park, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Brook","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M. A.","family":"Calverley","sequence":"additional","affiliation":[{"name":"University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome R.","family":"Celli","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Crim","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Hartley","sequence":"additional","affiliation":[{"name":"Veramed Ltd., Twickenham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College of Cornell University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Newby","sequence":"additional","affiliation":[{"name":"University of Edinburgh, Edinburgh, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa A.","family":"Pragman","sequence":"additional","affiliation":[{"name":"Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota"},{"name":"University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Yates","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Niewoehner","sequence":"additional","affiliation":[{"name":"Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota"},{"name":"University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,1]]},"reference":[{"key":"2026032023221017100_bib1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","journal-title":"Lancet"},{"key":"2026032023221017100_bib2","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1161\/01.CIR.0000056767.69054.B3","article-title":"Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease","volume":"107","author":"Sin","year":"2003","journal-title":"Circulation"},{"key":"2026032023221017100_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1378\/chest.12-2847","article-title":"Cardiovascular comorbidity in COPD: systematic literature review","volume":"144","author":"M\u00fcllerova","year":"2013","journal-title":"Chest"},{"key":"2026032023221017100_bib4","doi-asserted-by":"crossref","first-page":"e83725","DOI":"10.1371\/journal.pone.0083725","article-title":"A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study","volume":"8","author":"Shibata","year":"2013","journal-title":"PLoS One"},{"key":"2026032023221017100_bib5","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agust\u00ed","year":"2012","journal-title":"PLoS One"},{"key":"2026032023221017100_bib6","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"key":"2026032023221017100_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032023221017100_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1164\/rccm.201206-1113OC","article-title":"Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease","volume":"186","author":"Thomsen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023221017100_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/COPD.S4854","article-title":"Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation","volume":"4","author":"Bathoorn","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026032023221017100_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.rmed.2008.12.006","article-title":"Clinical, functional and biochemical changes during recovery from COPD exacerbations","volume":"103","author":"Koutsokera","year":"2009","journal-title":"Respir Med"},{"key":"2026032023221017100_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(14)61136-3","article-title":"The role of the microbiome in exacerbations of chronic lung diseases","volume":"384","author":"Dickson","year":"2014","journal-title":"Lancet"},{"key":"2026032023221017100_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(09)70331-7","article-title":"Role of acute infection in triggering acute coronary syndromes","volume":"10","author":"Corrales-Medina","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2026032023221017100_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jama.2014.18229","article-title":"Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease","volume":"313","author":"Corrales-Medina","year":"2015","journal-title":"JAMA"},{"key":"2026032023221017100_bib14","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1056\/NEJMoa041747","article-title":"Risk of myocardial infarction and stroke after acute infection or vaccination","volume":"351","author":"Smeeth","year":"2004","journal-title":"N Engl J Med"},{"key":"2026032023221017100_bib15","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1136\/heartjnl-2015-307691","article-title":"Acute myocardial infarction and influenza: a meta-analysis of case-control studies","volume":"101","author":"Barnes","year":"2015","journal-title":"Heart"},{"key":"2026032023221017100_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection","volume":"378","author":"Kwong","year":"2018","journal-title":"N Engl J Med"},{"key":"2026032023221017100_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"key":"2026032023221017100_bib18","first-page":"261","article-title":"Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT\u00ae trial","volume":"189","author":"Halpin","year":"2011","journal-title":"Hai"},{"key":"2026032023221017100_bib19","first-page":"A1014","article-title":"Acute exacerbations of chronic obstructive pulmonary disease increase subsequent cardiovascular event risk: A secondary analysis of adjudicated SUMMIT study data [abstract]","volume":"195","author":"Kunisaki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023221017100_bib20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1183\/09031936.00087312","article-title":"The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol","volume":"41","author":"Vestbo","year":"2013","journal-title":"Eur Respir J"},{"key":"2026032023221017100_bib21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2026032023221017100_bib22","volume-title":"Standardized definitions for end point events in cardiovascular trials","author":"Hicks","year":"2010"},{"key":"2026032023221017100_bib23","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026032023221017100_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.06-0668","article-title":"Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD","volume":"131","author":"Pinto-Plata","year":"2007","journal-title":"Chest"},{"key":"2026032023221017100_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.200705-678OC","article-title":"Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease","volume":"177","author":"Bozinovski","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023221017100_bib26","doi-asserted-by":"crossref","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/1\/51\/67117355\/ajrccm_198_1_51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/1\/51\/67117355\/ajrccm_198_1_51.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:22:26Z","timestamp":1774063346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/198\/1\/51\/8498101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,7,1]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201711-2239oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7]]},"published":{"date-parts":[[2018,7,1]]}}}